Johnson and Johnson
Johnson and Johnson reported sales of $20.7 billion; sales grew by 3.3%. The sales were driven by Stelara (ustekinumab), Darzalex (daratumumab), and Imbruvica (ibrutinib), Invega Sustenna/Xeplion/Invega Trinza/Trevicta (paliperidone palmitate). Generic or biosimilar competition of Velcade (bortezomib), Remicade (infliximab), and Procrit (epoetin alfa) slowed the growth of these products.
Also see: Janssen collaborated with Apple to check if a new iPhone app can reduce the risk of stroke
Roche Roche presented a slight increase in the revenues compared to last year for the first quarter. The company has reported $15.7 billion in terms of revenues. Gardasil/Gardasil 9 reported sales of %1.1 billion in the first quarter.
Also read: Roche’s Rozlytrek approved for the NTRK fusion-positive advanced recurrent solid tumors in Japan
Novartis Novartis announced their Q1 2020, net sales of $ 12.3 billion. Entresto and Cosentyx mostly drove the sales. The company has reported only a 1% increase in sales of Gilenya. The sales of Revolade were increased by 31%, adding $403 million.
Also read: FDA approved Novartis’ Tabrecta for NSCLC with METex14
Merck Merck is reporting exceptional financial reports since some quarters, thanks to the sales of Keytruda. The company has reported sales of $ 12.1 billion; the company reported Keytruda sales as $3.3 billion. The company has reported an increase of 11% in sales. Pfizer Pfizer has reported sales of $12 billion, 7% in the functional decline. GSK GSK reported $ 11.4 billion (£9.1 billion) in the first quarter of 2020. Pharmaceuticals sales accounted for £4.4 billion, vaccines for 1.8 billion, and consumer healthcare accounted for £2.9 billion. HIV sales accounted for £1.2 billion, and respiratory sales accounted for £871 million.